Tissue Factor (TF), a small transmembrane glycoprotein, is the cellular receptor for the zymogen Factor VII and the serine protease Factor VIla (VIla). TF provides cofactor function for VIIa in the catalytically active (TF:VIIa) binary complex. To explore the structural loci of TF that are responsible for binding of VII and VIIa, monoclonal antibodies (MAbs) and sequence-specific polyclonal antibodies to the native TF protein were analysed for inhibition of VII binding. Two independent epitopes of MAbs were localized by reciprocal competition and by binding of the MAbs to different proteolytic fragments of TF. The epitopes were also characterized in part by progressive C-terminal deletional mutation of the TF protein. Reactivity of the anti-(locus II) MAb TF9-6G4 is consistent with epitope localization in residues Thr40-Val83, encoded by exon 3. In contrast, the anti-(locus I) MAb TF9-5G9 was reactive with fragments encompassing exon 4 (Thr106-Lys"65). Antibodies to linear sequences encoded by the same two exons also inhibited VII binding. These data suggest a minimum requirement for two of the four exon-encoded regions of TF for the functional integrity of this receptor cofactor with respect to ligand recognition and high-affinity binding.
INTRODUCTION
Cellular initiation of coagulation is efficiently mediated by Tissue Factor (TF) (Maynard et al., 1975) , the cell-surface receptor for the coagulation zymogen Factor VII and the receptor and cofactor for the serine protease Factor VIIa (VITa) (Broze, 1982) . Protein-protein interactions between Vlla and the extracellular domain of TF are considered to be essential for both receptor and cofactor functions, the latter being defined as the catalytic enhancement of VIIa-mediated proteolytic activation of the zymogen substrates Factors X and IX (Bach, 1988) . It has been inferred that conformational alterations of the VIla protease domain that are required for proper alignment of the catalytic triad occur upon binding to TF . Positive co-operativity has been observed for the binding of VII to purified TF as well as to TF expressed as an integral cell-membrane protein (Bach et al., 1986; Fair & MacDonald, 1987) . These studies indicate that TF may preferably function as a dimer.
Although the primary sequence of this small cell-surface receptor cofactor has been established, functional sites which provide the interactive region for VII binding have not been defined. Certain inhibitory antibodies to TF have been shown to block VII binding, demonstrating that binding is a critical requirement for cofactor function, namely the formation of a catalytically active (TF:VIla) complex (Carson et al., 1985; Morrissey et al., 1988b) . The limited surface area [6.4-7.5 nm2 (640-750 A2)] of antibody 'footprints' on proteins (Davies et al., 1988) suggests that monoclonal antibodies (MAbs) may serve as highly specific probes for relatively small solvent-exposed loci on proteins, and thereby may help to identify functional regions. Despite the potential caveat of secondary allosteric effects, antibodies have provided topographical insight into the structure and function of proteins (Dueweke & Gennis, 1990; Brakenhoff et al., 1990; Westmeyer et al., 1990) . In the present study we 
Proteins
Human Factor VII was purified from plasma as described (Fair, 1983) . Twenty-four hybridomas producing MAbs against TF have previously been described in detail (Morrissey et al., 1988b) . Hybridomas were propagated in ascites growth and the MAbs were purified from ascites using adsorption of MAb to immobilized Protein A in the presence of 1.5 Mglycine/3 M-NaCl, pH 8.9, followed by elution with 100 mmcitric acid, pH 4.0. Human brain TF was purified as described (Morrissey et al., 1988a) . All proteins were of the expected size and were homogeneous by SDS/PAGE (Laemmli, 1970) .
Antibodies of predetermined specificity were produced by peptide immunization followed by affinity purification on immobilized TF. The peptides were based on the primary amino acid sequence of human TF and were synthesized on an Applied Biosystems Model 430 synthesizer using standard t-butoxycarbonyl chemistry and HF cleavage. All peptides had a C-terminal cysteine which was coupled to keyhole-limpet haemocyanin (KLH) via an m-maleimidobenzoyl N-hydroxyVol. 278
Abbreviations used: TF, Tissue Factor; VII/VIla, Factor VII/VITa; MAb, monoclonal antibody; KLH, keyhole-limpet haemocyanin; TBS, 20 mmTris/150 mM-NaCl, pH 7.4. succinimide ester linkage (Liu et al., 1979 (Cleveland et al., 1977) . Once the proteins had entered the stacking gel, electrophoresis (Laemmli, 1970) was interrupted for 30 min to allow proteolytic digestion at ambient temperature. After completion of electrophoresis, the proteins were transferred to nitrocellulose (Schleicher and Schuell, Keene, NH, U.S.A.), followed by blocking with 5 % (w/v) non-fat dry milk in 20 mmTris/ 150 mM-NaCl, pH 7.4 (TBS). Reactivity of antibodies was analysed by incubating the nitrocellulose membranes with 1:10-diluted culture supernatant from individual hybridomas, or with affinity-purified peptide-specific antibody at 10 utg/ml in 50% non-fat dry milk in TBS. This was followed by five washes in TBS and detection of bound antibody by an appropriate alkalinephosphatase-coupled secondary antibody using NitroBlue Tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate in 0.1 MTris/0.1 M-NaCI/5 mM-MgCl2, pH 9.5, as a colour-developing reagent.
Binding assays
Binding analysis of radiolabelled molecules to cell-surface TF were performed on a J82 cell monolayer (ATCC HTB 1) in the presence of 5 mM-CaCI2 as previously described (Drake et al., 1989 All MAbs to TF produced in the laboratory had either overlapping epitopes with the two loci described here or an additional non-overlapping locus. We were not able to assign the epitope for this latter group of MAbs by the approaches described in this paper. MAbs to locus I included inhibitory (TF8-5G9) as well as non-inhibitory (TF9-lOH10) MAbs (Morrissey et al., 1988b (Fig. 1) . MAbs TF8-5G9 (against locus I) and TF9-6G4 (against locus II) inhibited VII binding in a concentration-dependent 
Epitope localization of anti-TF MAbs
The entire panel of previously described anti-TF MAbs (Morrissey et al., 1988b) was reactive with the TF extracellular domain (residues 1-219) , which is encoded by exons 2-5 (Mackman et al., 1989) . In order to localize the epitopes, we analysed the MAbs for reactivity with proteolytic fragments derived from a Staphylococcus aureus V8 protease partial digest of TF. Whereas no reactivity of the anti-(locus I) MAb TF9-lOHF10 with proteolytic fragments ofTF was observed, the partially overlapping and inhibitory anti-(locus I) MAb TF8-5G9 consistently reacted with a 27 kDa V8 fragment (Fig. 2) . The N-terminal residue of this fragment has been determined as Thr'06 (Morrissey et al., 1987) , the first amino acid in the exon 4-encoded region ofTF (Mackman et al., 1989) . Immunopurification of a 27 kDa fragment from a V8 digest of TF using immobilized TF8-5G9 and N-terminal sequence analysis of the fragment confirmed that exon 4-encoded sequences were recognized by the MAb. In addition, the pattern of reactivity of TF8-5G9 (Fig. 2 Cleveland et al. (1977) for 30 min at ambient temperature, followed by electrophoretic separation under non-reducing conditions and transfer to nitrocellulose. The the TF extracellular domain appeared to be more reactive compared with antibodies reactive with more N-terminal aspects of the protein, if antibody binding to nitrocellulose-bound TF was analysed. Two lower-molecular-mass fragments were detected by the sequence-specific antibody to TF-161-189 which encompass the N-terminal sequence encoded by exon 5. The reactivity of anti-TF-161-189 with a fragment of approx. 18 kDa indicates that the fragment may be identical to a predominant V8 protease fragment, with Phe'75 as the N-terminal residue (Morrissey et al., 1987) . TF8-5G9 was not reactive with these fragments, suggesting that the TF8-5G9 epitope was encoded by exon 4 rather than exon 5. TF8-5G9 does not react with reduced TF (Morrissey et al., 1988b) . Since the analysis was performed under non-reducing conditions, the lack of reactivity with the 18 kDa fragment encompassing the C-terminal disulphide loop (Cys186-Cys209) of TF indicates that TF8-5G9 is not reactive with the disulphide loop itself or adjacent sequences alone. We therefore suggest that residues in exon 4 contribute to the TF8-5G9 epitope, which is dependent on participation of the disulphide loop in exon 5 for proper expression. We tested binding of TF8-5G9 to short (10-30 residues) synthetic peptides based on the TF sequence, as well as competition of synthetic peptides with TF binding of TF8-5G9. Both attempts to further localize the epitope of TF8-5G9 failed. These data are consistent with current concepts of conformational epitopes on proteins which are formed by [15] [16] [17] [18] [19] [20] [21] [22] amino acid residues in a non-linear sequence display on several surface-oriented loops of proteins (Laver et al., 1990) .
The anti-(locus II) MAb TF9-6G4 was reactive with certain V8 protease fragments which were also detected by purified antipeptide antibodies to an N-terminal proximate aspect of TF (Fig.  2) . The patterns of recognition of TF by anti-(locus I) MAb TF8- (Fig. 3) . Reactivity of TF9-6G4, but not of an unrelated control MAb, was observed with anti-TF-1-157 and anti-TF-1-83 (Fig. 3) (Dueweke & Gennis, 1990; Brakenhoff et al., 1990; Westmeyer et al., 1990 MAbs TF8-5G9 and TF9-6G4 were demonstrated to react with non-overlapping epitopes. Additional MAbs were reactive with the same loci identified by TF8-5G9 (locus I) and TF9-6G4 (locus II). Among the MAbs reactive with locus II was TF9-5B7, a MAb which has been successfully used to prophylactically intervene against the lethality of gram-negative septic shock in baboons (Taylor et al., 1991) . Both anti-(locus I) MAb TF8-5G9 and anti-(locus II) MAb TF9-6G4 inhibited VII binding to TF in a concentration-dependent manner. This suggests either that the MAb epitopes overlap the VII binding site or that binding of the MAbs conformationally perturbs TF to prevent VII binding However, this is not a general property of any antibody associated with TF, since certain sequence-specific antibodies as well as one MAb (TF9-lOH 10) were shown not to interfere in TF receptor function.
We here demonstrate that the neutralizing MAb TF8-5G9 reacted with a proteolytic fragment spanning the C-terminal half of the TF extracellular domain starting at residue Thr 06, the amino acid encoded by the 5' codon of exon 4. This MAb was not reactive with shorter fragments spanning most ofthe sequence of exon 5, suggesting that exon 4 encodes residues critical to this locus I epitope. Reactivity of anti-(locus II) MAb TF9-6G4 with proteolytic fragments as well as with progressive C-terminal deletion mutants of TF suggested that within the sequence 40-83 are residues necessary for this epitope. This sequence shows a rather low degree of identity to the mouse TF sequence (Hartzell et al., 1989) , thus making it a potential epitope. The analysis of MAb epitopes thus confirms the inhibition pattern observed with antibodies specific for linear sequences of TF. Both analyses establish that binding of antibodies to epitopes encoded by exon 3 and exon 4 of TF results in a loss of TF receptor function. Therefore residues in more than one single exon-encoded linear sequence of TF are implicated in receptor function.
MAb-defined epitopes on proteins are most commonly constituted by residues which are not derived from a single linear sequence (Laver et al., 1990) , as demonstrated by crystallography of MAb-protein complexes and more recently by hydrogen-deuterium exchange protection analysis (Paterson et al., 1990) . MAb binding to a receptor may resemble the interaction of the natural ligand with respect to occupancy of a circumscribed solvent-accessible protein surface. The affinity of some MAbs for binding to TF is comparable with and even exceeds that of the natural ligand, VII (Drake et al., 1989) . The MAb 'footprint' can reasonably be assumed to consist of spatially proximate amino acid residues rather than a linear sequence. This may explain the advantage of the MAb analysis presented here and the difficulties we have encountered in identifying peptidyl mimetics based on the linear sequence of TF. Mimicry of one site by a linear peptide, even if adopting a favourable conformation, may not result in a sufficient loss of binding function when several additional sites contribute significantly to the binding energy. The functional regions of the TF sequence identified by the antibody analysis are thus likely to represent regions on the TF surface which are part of or in proximity to the VII-interactive sites. These could consist of two remote sequences forming a complex contiguous region of the folded protein or of two spatially separate interactive areas which interact with independent sites on VII. The interaction with independent and separate sites on VII might represent the structural counterpart of the two functional properties of TF, namely to serve as receptor and cofactor for VIIa. Recent studies have indeed identified two structural sites on VIla which contribute to the high-affinity binding of the protease to its receptor, namely the VIIa y-carboxyglutamic acid-domain (Sakai et al., 1990) and residues 195-206 in the catalytic domain (Wildgoose et al., 1990) . In addition, a distant homology search suggested that TF is related to the interferon and cytokine receptor superfamily (Bazan, 1990) . Accordingly, the TF extracellular domain may consist of two structurally similar domains in tandem, each of which provides an interactive site for the ligand (Bazan, 1990) . Our study would be consistent with the proposed model, which will require additional verification by independent approaches.
